oncology

Cancer: drugs, tests, devices and services for diagnosing and treating it.

Theme · 23 companies · 5 report it as a revenue line

Show
8-K events
Match any selected event
8-K event types
More events

Only filters 8-Ks. Other selected forms stay visible.

Role
  • ABBV AbbVie

    Sells it“AbbVie’s oncology products target some of the most complex and difficult-to-treat cancers.”

    Latest 10-QQ3 FY2026Positive ·

    Skyrizi and Rinvoq more than offset Humira erosion; lower acquired R&D and impairment charges amplify the earnings rebound.

    • Revenue$17.4BYoY +10.3%
    • Net income$4.2Bvs $186.0M year ago
  • ABT Abbott Laboratories

    Sells it“The acquisition adds Cologuard, Oncotype DX and Cancerguard, establishing Abbott in cancer diagnostics.”

    Latest 8-KExecutive pay ·

    Change-in-control agreements extended through Dec. 31, 2028 for named executives except CEO Robert B. Ford, whose agreement expires Dec. 31, 2026.

  • AMGN Amgen

    Sells it 17%, $6.2B a year“BLINCYTO was launched in 2014 and has proven efficacy in a wide range of patients with CD19-positive B-cell acute lymphoblastic leukemia (B-ALL), including those who are MRD(–) or MRD(+) in frontline consolidation, and those with relapsed or refractory (R/R) disease.”

    Latest 10-QQ3 FY2026 ·

    Repatha, UPLIZNA and IMDELLTRA demand more than offsets biosimilar erosion in Prolia and XGEVA.

    • Revenue$10.4BYoY +8.5%
    • Net income$3.9BYoY +20.1%
  • BLSM BlossomHill Therapeutics, Inc.

    In development“We are a clinical-stage biopharmaceutical company applying our intentional, chemistry-based approach to develop innovative small molecule medicines that address significant unmet medical needs in cancer treatment.”

    Latest 424B4final IPO prospectusBankruptcy / going concernPre-revenue ·

    Develops small-molecule cancer drugs; $150M all-primary raise funds trials led by BH-30643 for treatment-resistant lung cancer.

  • BMY Bristol-Myers Squibb

    Sells it 48%, $22.9B a year“It has been approved for several anti-cancer indications including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer.”

    Latest 10-QQ3 FY2026MixedImpairment / charge ·

    Eliquis drove growth as generics eroded Revlimid and Pomalyst; pipeline licensing charges weighed on earnings.

    • Revenue$13.1BYoY +6.9%
    • Net income$2.2BYoY −1.8%
  • BRKR Bruker

    Sells it“Used in oncology, inflammation, neurology, and cardiovascular disorders, as well as metabolic disease, drug discovery, and bone diseases.”

    Latest 8-KLeadership change ·

    Board adds immunologist Eicke Latz as life-science work expands; declares $0.05/share quarterly dividend.

  • BSX Boston Scientific

    Sells it“Interventional Oncology & Embolization”

    Latest 8-KLeadership changeExecutive pay ·

    David S. Wichmann to succeed Ludwig as lead independent director; 2027 executive incentives tie payouts to sales, adjusted EPS and shareholder returns

  • ETRA Electra Therapeutics, Inc.

    In development“We are conducting a Phase 1 clinical trial evaluating ipsoprubart as a monotherapy in patients with relapsed/refractory T cell and natural killer (NK) cell malignancies, with initial data expected in the second half of 2027.”

    Latest 424B4final IPO prospectusMixedBankruptcy / going concernPre-revenue ·

    Develops antibodies to remove disease-driving immune cells; $350M all-primary raise funds ipsoprubart’s registrational trials

  • GILD Gilead Sciences

    Sells it“Trodelvy grew on higher demand; total oncology revenue rose 9%.”

    Latest 10-QQ3 FY2026Impairment / charge ·

    Acquisition charges and the EVOKE-03 write-off drove a YTD loss despite stronger Biktarvy and Yeztugo sales.

    • Revenue$8.3BYoY +6.8%
    • Net income$2.4BYoY −20.4%
  • IAM Iambic Therapeutics, Inc.

    In development“Additionally, we are engaged in a number of discovery stage programs in indications, including oncology, metabolic disease and endocrinology, which we estimate represent an over $70 billion in aggregate global commercial opportunity.”

    Latest 424B4final IPO prospectusPositivePre-revenueCustomer concentration ·

    AI-driven drug developer raises $150M to advance lead HER2 cancer candidate IAM1363 and its pipeline

  • ISRG Intuitive Surgical

    Supplies it“Radical prostatectomy is the removal of the prostate gland in patients diagnosed with clinically localized prostate cancer.”

    Latest 8-KLeadership change ·

    Humana insurance chief Aaron Martin appointed independent director, expanding the board effective Jan. 1, 2027.

  • JNJ Johnson & Johnson

    Sells it“Oncology (e.g., prostate cancer, hematologic malignancies, lung cancer and bladder cancer)”

    Latest 10-QQ3 FY2026MixedRestructuringImpairment / chargeLegal / investigation ·

    TREMFYA and oncology growth offset STELARA’s biosimilar erosion, but a proposed talc-settlement charge nearly wiped out earnings.

    • Revenue$25.4BYoY +5.9%
    • Net income$210.0MYoY −95.9%
  • LLY Eli Lilly and Company

    Sells it 14%, $9.4B a year“For use as monotherapy or in combination with endocrine therapy for the treatment of HR+, HER2- metastatic breast cancer, and in combination with endocrine therapy for treatment of HR+, HER2-, node positive, early breast cancer at high risk of recurrence.”

    Latest 10-QQ3 FY2026PositiveImpairment / charge ·

    Mounjaro and Zepbound volume growth outweighed lower prices, while acquired research charges constrained profit growth.

    • Revenue$24.4BYoY +38.6%
    • Net income$6.5BYoY +15.5%
  • MCK McKesson Corporation

    Sells it“Oncology & Multispecialty growth reflected specialty pharmaceutical sales and provider solutions, partly offset by higher costs and the absence of a prior-year $51 million investment-sale/market-decision gain.”

    Latest 10-QQ2 FY2027Restructuring ·

    Precision Medicine Group and Spectrum Vision acquisitions expand specialty care as separation costs squeeze Medical-Surgical profit.

    • Revenue$111.0BYoY +7.6%
    • Net income$1.2BYoY +9.7%
  • MRK Merck & Co.

    Sells it 54%, $34.9B a year“approved as monotherapy for the treatment of certain patients with cervical cancer, classical Hodgkin lymphoma (cHL), cutaneous squamous cell carcinoma, esophageal or gastroesophageal junction (GEJ) carcinoma, head and neck squamous cell carcinoma (HNSCC), hepatocellular carcinoma (HCC), melanoma, Merkel cell carcinoma, microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) solid tumors (including MSI-H/dMMR colorectal cancer and endometrial carcinoma), non-small cell lung cancer (NSCLC), primary mediastinal large B-cell lymphoma (PMBCL), tumor mutational burden-high (TMB-H) solid tumors, and urothelial cancer including non-muscle invasive bladder cancer.”

    Latest 8-KLeadership change ·

    Douglas M. Baker Jr. succeeds Thomas H. Glocer as independent lead director Jan. 1, 2027, ahead of Glocer’s May 2027 board retirement.

  • MRNA Moderna

    In development“In Phase 3 INTerpath-001 melanoma, intismeran autogene plus Merck’s KEYTRUDA reduced recurrence or death risk by 42% (HR 0.58; 95% CI 0.45–0.75; p<0.001) and distant-metastasis or death risk by 38% (HR 0.62; 95% CI 0.45–0.85; p=0.002) after median follow-up of 24.6 months.”

    Latest 8-KPositiveDebt financing ·

    Credit amendment cuts initial and delayed-draw term-loan margins 75 bp and extends maturity to November 2031.

  • MYGN Myriad Genetics

    Sells it 60%, $494.1M a year“In oncology, we offer testing for patients across their cancer journey, from identification of genes that increase cancer risk, to predicting whether they are candidates for targeted treatments.”

    Latest 8-KExecutive pay ·

    One-time retention options for the CFO, COO and chief scientific officer support leadership continuity as Myriad works to improve efficiency.

  • NUOX NuvOx Therapeutics, Inc.

    In development“NanO2 is being developed as a radiation therapy sensitizer providing an oxygen supplement to facilitate oxygen free radical generation.”

    Latest S-1/Aamended IPO prospectusNegativeBankruptcy / going concernRestatementAccounting issue ·

    Intravenous oxygen drug developer seeks $20M gross at IPO midpoint to advance NanO₂ trials, with glioblastoma results the next major test

  • PFE Pfizer

    Sells it“Innovative oncology product portfolio of ADCs, small molecules, bispecifics and other immunotherapies that treat a wide range of cancers including certain types of breast cancer, genitourinary cancer and hematologic malignancies, as well as certain types of melanoma, gastrointestinal, gynecological and lung cancer – select products include: Ibrance, Xtandi, Padcev, Adcetris, Inlyta, Lorbrena, Bosulif, Tukysa, Braftovi, Mektovi, Orgovyx, Elrexfio, Tivdak and Talzenna.”

    Latest 8-KCEO/CFO change ·

    Interim CFO Cecile Guegan appointed permanent CFO and EVP, effective Nov. 1.

  • REGN Regeneron Pharmaceuticals

    Sells it“Libtayo received Japanese approval in cutaneous squamous cell carcinoma.”

    Latest 10-QQ3 FY2026Positive ·

    Dupixent growth and richer Sanofi profit sharing more than offset EYLEA erosion, deepening reliance on the partnership.

    • Revenue$5.1BYoY +36.3%
    • Net income$1.9BYoY +33.5%
  • SDGR Schrödinger, Inc.

    Supplies it“We have entered into drug discovery collaborations with biopharmaceutical companies under which our collaborators are pursuing research in a number of therapeutic areas, including programs in oncology, antifungal diseases, fibrosis, inflammatory bowel disease, metabolic disease, autoimmune disease, immuno-oncology, cardiopulmonary disease, CNS diseases, and tuberculosis.”

    Latest 10-QQ3 FY2026 ·

    Structure Therapeutics milestone drove revenue growth; hosted migration obscured stronger software contracting.

    • Revenue$64.5MYoY +18.7%
    • Net income−$37.7MYoY −15.0%
  • STA Starton Holdings, Inc.

    In development“We are a clinical-stage biotechnology company focused on improving standard-of-care therapies for people with cancer through application of our proprietary platform of delivery technology systems.”

    Latest S-1/Aamended IPO prospectusNegativeBankruptcy / going concernAccounting issuePre-revenue ·

    Develops continuous-delivery lenalidomide for blood cancers; offering funds trials but further capital is needed to reach approval

  • TWST Twist Bioscience

    Supplies it“This covers liquid biopsy for therapy selection, multicancer screening (multicancer early detection and multicancer detection) and molecular residual disease (MRD), plus comprehensive genomic profiling (CGP) of tissue;”

    Latest 10-KFY2026Positive ·

    AI-enabled drug discovery lifts DNA Synthesis and Protein Solutions, but commercial hiring and litigation absorb gross-profit gains.

    • Revenue$459.4MYoY +22.0%
    • Net income−$130.2MYoY −67.6%

Feedback